RISANKIZUMAB
risankizumab 150 mg/mL injection, 1 mL pen device
RISANKIZUMAB (14142H)
14142H
Manner of administration:Injection
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Whole body
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Continuing treatment, Face, hand, foot
Restriction
Indication: Severe chronic plaque psoriasis
Treatment phase: Balance of supply - Continuing treatment, Whole body or Continuing treatment, Face,
hand, foot
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $5,140.26 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Skyrizi | |||||